Form 13-F position report

CERO THERAPEUTICS HLDGS INC

Reported by Avantax Planning Partners Inc

PBAX CUSIP 71902K105 Manager CIK 0001005441

Reported 0 shares, down 2,585,151 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 4 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-06-30 23920
2024-09-30 126993
2024-12-31 155109
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

4 quarters
Quarterly reported position history for CERO THERAPEUTICS HLDGS INC held by Avantax Planning Partners Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -2,585,151 (-100.0%) 0 $0 2025-04-29
Q4 2024 Added 2,585,151 +1,224,021 (89.9%) < 0.01% $155,109 2025-02-07
Q3 2024 Added 1,361,130 +1,281,130 (1601.4%) < 0.01% $126,993 2024-11-14
Q2 2024 New 80,000 +80,000 (0.0%) < 0.01% $23,920 2024-08-09

Who else reported the position

21 managers reported CERO THERAPEUTICS HLDGS INC for Q1 2025.

Managers reporting CERO THERAPEUTICS HLDGS INC in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Tower Research Capital LLC TRC Reduced 0 -73,670 0 $0 3 qtrs
Cubist Systematic Strategies LLC Reduced 0 -333,442 0 $0 2 qtrs
Marex Group plc Reduced 0 -15,000 0 $0 2 qtrs
Guidance Point Advisors LLC Reduced 0 -18,717 0 $0 2 qtrs
JPMorgan Chase & Co Reduced 0 -140 0 $0 5 qtrs
Selkirk Management LLC Reduced 0 -121,040 0 $0 3 qtrs
Revolve Wealth Partners LLC Reduced 0 -32,799 0 $0 2 qtrs
JANE STREET GROUP LLC Reduced 0 -57,459 0 $0 5 qtrs
The Goldman Sachs Group Inc Reduced 0 -162,474 0 $0 2 qtrs
Avantax Planning Partners Inc This report Reduced 0 -2,585,151 0 $0 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
April 29, 2025
Filing type
13F-HR
Position type
CLASS A COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.